Dr. Zev A. Wainberg

About Zev A. Wainberg

Education:

• Earned an MD from the Sackler School of Medicine, New York Program at Tel Aviv University in 2003.
• Completed Internship and Residency in Internal Medicine at Montefiore Medical Center Moses Division Hospital (2001-2003).
• Fellowship in Hematology/Oncology at UCLA School of Medicine, finished in 2006.
• Board Certified in Medical Oncology by the American Board of Internal Medicine in 2006.

Experience:

• Professor of Medicine at UCLA and Co-director of the UCLA GI Oncology Program.
• Specializes in designing GI cancer clinical trials, with a focus on colon, gastric, and esophageal cancers.
• Research interests include gene expression patterns in GI cancers and the development of novel therapies.

Area of expertise

Affiliated Hospitals

UCLA

University Of California, Los Angeles

Clinical Trials Zev A. Wainberg is currently running

DFP-14927

for Cancer

This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.

Recruiting

1 award

Phase 1

10 criteria

TRE-515

for Cancer

TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, rapid and upregulated DNA replication creates high replication stress, as such, cancer cells are more susceptible than normal cells to perturbations in nucleotide metabolism by DNA-targeting treatments such as TRE-515. The Primary objective is to determine the safety and maximum tolerability of TRE-515 when administered orally once daily as a single agent. The secondary objectives are to establish a recommended phase 2 dose (RP2D), to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of TRE-515, preliminary evaluation of antitumor activity, and to determine the effect of an acid reducing agent (ARA) on TRE-515 exposure. The exploratory objectives are to evaluate the relationship between TRE-515 exposure and plasma deoxynucleoside concentrations, evaluate the relationship between TRE-515 exposure and reductions in intracellular dCK on-target knockdown as measured by a \[18F\]-clofarabine (CFA) positron emission tomography (PET) probe, to evaluate the relationship between TRE-515 treatment and dCK and CDA gene expression in archived tumor tissue when available, to evaluate the relationship between tumor CDA and plasma deoxynucleoside (dC and dU) concentrations, and to explore the effect of TRE-515 treatment on gene expression in white blood cell populations.

Recruiting

1 award

Phase 1

3 criteria

More about Zev A. Wainberg

Clinical Trial Related

4 years of experience running clinical trials · Led 33 trials as a Principal Investigator · 6 Active Clinical Trials

Other Doctors you might be interested in

Frequently asked questions